Gene transfer approaches for the treatment of inflammatory bowel disease.
The pathogenesis of Crohn's disease and ulcerative colitis, the two major forms of inflammatory bowel disease, involves a complex interplay between certain genetic, environmental and immunological factors. Considerable research progress in the last decade defined key inflammatory pathways in the inflamed gut and identified new potential therapeutic targets. Since the current medical treatment with corticosteroids and anti-inflammatory drugs is often associated with undesired side effects and cannot completely cure IBD, these current advances in our understanding of intestinal pathology may now allow the development of new biologic treatment strategies including gene therapy. In this review, we will give a brief overview of potential gene therapy target molecules related to chronic intestinal inflammation. Furthermore, we summarize the results of recent preclinical studies for intestinal gene transfer and discuss future perspectives.
Laboratory of Immunology, I. Medical Clinic, University of Mainz, Germany.
S
S
Wirtz
M F
MF
Neurath
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D001424:Bacterial Infections / Q000276:immunology; D003093:Colitis, Ulcerative / Q000276:immunology / Q000628:therapy; D003424:Crohn Disease / Q000276:immunology / Q000628:therapy; D016207:Cytokines / Q000235:genetics / Q000276:immunology; D004195:Disease Models, Animal; D015870:Gene Expression; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D015212:Inflammatory Bowel Diseases / Q000276:immunology / Q000628:therapy*; D007422:Intestines / Q000276:immunology; D033581:Stem Cell Transplantation
D016207:Cytokines